Table 3.

Relative risks (RR) of breast cancer death associated with each risk classifier among ER-positive patients, stratified by treatment with tamoxifen.

	Cases		Controls
Risk classifier	n	%	n	%	RR1	95% CI	RR2	95% CI
Tamoxifen treated (49 cases and 112 controls)
HOXB13:IL17BR
Low risk	19	39%	58	52%	1.0	ref	1.0	ref
High risk	30	61%	54	48%	1.9	0.9 - 3.7	1.5	0.7 - 3.2
MGI
Low risk	12	24%	55	49%	1.0	ref	1.0	ref
High risk	37	76%	57	51%	2.9	1.3 - 6.2	2.1	0.8 - 5.5
MGI+HOXB13:IL17BR
Low risk	12	24%	55	49%	1.0	ref	1.0	ref
Intermediate risk	14	29%	31	28%	1.8	0.7 - 4.8	1.3	0.4 - 4.2
High risk	23	47%	26	23%	3.5	1.5 - 8.1	2.7	0.9 - 7.5
BCI
Low risk	13	27%	61	54%	1.0	ref	1.0	ref
Intermediate risk	15	31%	29	26%	2.2	0.9 - 5.6	2.1	0.8 - 6.0
High risk	21	43%	22	20%	4.2	1.7 - 10.3	3.3	1.1 - 10.3
Tamoxifen untreated (90 cases and 174 controls)
HOXB13:IL17BR
Low risk	41	46%	101	58%	1.0	ref	1.0	ref
High risk	49	54%	73	42%	1.6	1.0 - 2.7	1.3	0.8 - 2.3
MGI
Low risk	32	36%	99	57%	1.0	ref	1.0	ref
High risk	58	64%	75	43%	2.6	1.5 - 4.8	1.7	0.8 - 3.4
MGI+HOXB13:IL17BR
Low risk	32	36%	99	57%	1.0	ref	1.0	ref
Intermediate risk	27	30%	39	22%	2.5	1.3 - 4.8	1.7	0.8 - 3.6
High risk	31	34%	36	21%	2.9	1.4 - 5.8	1.6	0.7 - 3.8
BCI
Low risk	30	33%	108	62%	1.0	ref	1.0	ref
Intermediate risk	26	29%	28	16%	3.9	1.9 - 8.0	3.2	1.5 - 6.8
High risk	34	38%	38	22%	3.6	1.8 - 7.4	2.0	0.8 - 4.9

¹Univariate conditional logistic regression models include HOXB13:IL17BR, MGI, MGI+HOXB13:IL17BR or BCI; ²multivariable conditional logistic regression models include HOXB13:IL17BR, MGI, MGI+HOXB13:IL17BR or BCI plus tumor size (≤2.0,>2.0) and grade (well, intermediate, poor).